Who Owns CRISPR?

3Jenny Rood, The Scientist, April 3, 2015. http://www.the-scientist.com/?articles.view/articleNo/42595/title/Who-Owns-CRISPR-/.

The first US patent for CRISPR/Cas gene editing was awarded to Feng Zhang of the Broad Institute and MIT on April 15, 2014, however a second patent application was submitted seven months prior to Zhang’s by Jennifer Doudna of UC-Berkeley and Emmanuelle Charpentier of the Helmholtz Center for Infection Research in Germany.  Both Doudna/Charpentier and Zhang had been working on CRISPR/Cas systems with the controversy over who owns the CRISPR/Cas Intellectual property stemming from the first date both groups published.  Doudna was the first to demonstrate CRISPR/Cas systems ability to edit targeted DNA, however Zhang was the first to demonstrate that this technology can be used to edit human cells.  Since both groups have set up competing companies the fight over who owns this intellectual property could continue in the courts for many years.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply